[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7279
1. Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM: Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma; 2007 Jan;48(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
  • The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described.
  • There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 - 77 years).
  • The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years).
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis


2. Ikeda M, Okusaka T, Ueno H, Morizane C, Kojima Y, Iwasa S, Hagihara A: Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol; 2008 Oct;38(10):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Maximum Tolerated Dose. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716041.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Saltuklaroglu T, Kalinowski J: How effective is therapy for childhood stuttering? Dissecting and reinterpreting the evidence in light of spontaneous recovery rates. Int J Lang Commun Disord; 2005 Jul-Sep;40(3):359-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How effective is therapy for childhood stuttering? Dissecting and reinterpreting the evidence in light of spontaneous recovery rates.
  • BACKGROUND: Similar positive results (e.g. immediate decreases in stuttering frequency and a 60-80% recovery rate from stuttering) have been reported for numerous therapeutic protocols for treating childhood stuttering, many of which have been diametrically opposite in their orientations and implementations.
  • For example, Johnson advocated indirect treatments that simply advocated refraining from drawing any negative attention to childhood disfluencies as persistent and chronic stuttering was thought to progress via negative parental reactions to normal disfluencies.
  • In contrast, direct interventionists sought immediately to eliminate stuttered speech patterns by training 'corrected' speech models that usually involved some form of prolonged speech.
  • However, reports from speech and language therapists around North Carolina, USA, suggest much lower recovery rates in the children they treat (i.e.
  • 13.9% over a median therapeutic period of 3 years, which to the present authors is an indicator of therapeutic inefficiency and ineffectiveness).
  • AIMS: The discrepancy between these recovery rates calls for a re-examination of the efficacy of stuttering therapy for children, especially in light of recent statements from some therapies suggesting that therapy might be curative in nature.
  • MAIN CONTRIBUTION: Spontaneous and complete recovery (removing all overt and covert markers of the pathology) occurs in 60-80% of all children who display incipient stuttering behaviours.
  • As such, it appears that many claims of therapeutic success in children who stutter are confounded by the possibility of spontaneous recovery during the testing and intervention period.
  • Simply put, it is impossible to discriminate between recovery that would occur naturally over time, and what may have been simply accelerated via therapy.
  • Based on stable prevalence rates and the data in the present paper, it is suggested that therapy does little to boost recovery rates from incipient stuttering.
  • Therapy can provide 'inhibitory' symptomatic relief with varying degrees of success with respect to decreasing stuttering severity and the need for continued therapy.
  • However, it must be made clear that curing stuttering is not a likely outcome of therapy, although successful management can decrease the severity of the problem.
  • It is argued that all forms of stuttering inhibition, including those at work during spontaneous recovery, are all mediated by the degree of mirror neuron engagement in the brain.
  • CONCLUSIONS: It is proposed that in children who stutter, the best source of relief from stuttering is in the effective and efficient engagement of mirror neurons via methods that best replicate choral speech.
  • In order to induce natural sounding, fluent speech, it is suggested that one uses primarily derivations of choral speech such as altered auditory feedback.
  • Motoric techniques might also be used synergistically to provide supplementary sources of mirror neuron engagement.

  • MedlinePlus Health Information. consumer health - Stuttering.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16195194.001).
  • [ISSN] 1368-2822
  • [Journal-full-title] International journal of language & communication disorders
  • [ISO-abbreviation] Int J Lang Commun Disord
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


Advertisement
4. Styczynski J, Koltan A, Wysocki M: Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis. Neoplasma; 2006;53(2):168-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
  • Resistance to glucocorticoids remains one of the main obstacles in therapy of childhood acute lymphoblastic leukemia (ALL).
  • Concentration of both glucocorticoids in extracellular fluid was higher than drug resistance in the following groups of patients: in initial ALL patients, in patients staying in remission during follow-up, and in prednisolone good responders.
  • [MeSH-major] Drug Resistance, Neoplasm / physiology. Glucocorticoids / pharmacokinetics. Glucocorticoids / therapeutic use. Models, Theoretical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575474.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / P-Glycoproteins; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


5. Colina M, La Corte R, Trotta F: Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol; 2009 Jan-Feb;27(1):112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature.
  • Twelve of the 14 patients had a good response after 3 infusions and in 8 of these patients a sustained remission was observed.

  • Genetic Alliance. consumer health - SAPHO syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327238.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  • [Number-of-references] 19
  •  go-up   go-down


6. Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, Storb R, Riddell SR: Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res; 2009 Jul 15;15(14):4759-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
  • PURPOSE: Allogeneic nonmyeloablative hematopoietic stem cell transplant (NM-HSCT) can result in durable remission of chronic lymphocytic leukemia (CLL).
  • RESULTS: Eight of the 12 patients achieved remission or a major antitumor response and all 8 developed CD8(+) and CD4(+) T cells specific for antigens expressed by CLL.
  • CONCLUSIONS: The development of a diverse T-cell response specific for minor H and tumor-associated antigens expressed by CLL predicts an effective graft-versus-leukemia response after NM-HSCT.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1993-2003 [15774790.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1566-73 [15471955.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1029-33 [15830011.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3819-29 [15809448.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7757-63 [16278397.001]
  • [Cites] Blood. 2006 May 1;107(9):3779-86 [16391015.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1683-9 [16888617.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5060-9 [17075125.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 [17084369.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):87-97 [17222778.001]
  • [Cites] Br J Haematol. 2007 May;137(4):355-63 [17456058.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):340-52 [17438575.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Nat Med. 2000 Jun;6(6):667-72 [10835683.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7144-50 [11390460.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1159-62 [11590442.001]
  • [Cites] Nat Med. 2002 Apr;8(4):410-4 [11927949.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1063-70 [12393705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Leukemia. 2003 May;17(5):841-8 [12750695.001]
  • [Cites] Blood. 2003 Jul 15;102(2):571-6 [12576330.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2747-53 [12860954.001]
  • [Cites] Leukemia. 2004 Apr;18(4):798-808 [14973499.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):371-80 [15122208.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):397-405 [15864281.001]
  • [Cites] J Clin Invest. 2004 May;113(10):1498-510 [15146248.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1278-87 [15116118.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1075-82 [15039282.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2600-2 [15205268.001]
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):282-6 [2492101.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] J Immunol Methods. 1990 Apr 17;128(2):189-201 [1691237.001]
  • [Cites] N Engl J Med. 1991 Mar 7;324(10):667-74 [1994250.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):925-35 [7681471.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3048-54 [9108426.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2757-65 [9389740.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2197-207 [9490709.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):301-8 [9892612.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1992-2002 [10068672.001]
  • [CommentIn] Clin Cancer Res. 2009 Jul 15;15(14):4515-7 [19584145.001]
  • (PMID = 19567591.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114536-05; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / P01 CA018029-340049; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / P30 CA015704-35; United States / NCI NIH HHS / CA / CA078902-11; United States / PHS HHS / / 114536; United States / NCI NIH HHS / CA / CA015704-35; United States / NCI NIH HHS / CA / P01 CA078902-11; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / R01 CA114536-05; United States / NCI NIH HHS / CA / R01 CA114536; United States / NCI NIH HHS / CA / P01 CA078902; United States / NCI NIH HHS / CA / CA018029-340049
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Minor Histocompatibility Antigens; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS146416; NLM/ PMC2785487
  •  go-up   go-down


7. Cameron S, Savvoukidis T, Armbrust T, Haller F, Kitz J, Füzesi L, Ramadori G: Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. Med Oncol; 2010 Jun;27(2):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here on the very different long-term outcome of a synchronous metastatic GIST with complete remission of the primary tumor and progressive liver metastases under TKR-I therapy.
  • Fifty-two months after initial diagnosis, the patient died of liver failure.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] J Pathol. 2008 Sep;216(1):64-74 [18623623.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Oncol. 2006 Sep;17 Suppl 10:x280-6 [17018739.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4764-74 [16954519.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5352-9 [18955458.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1411-9 [18774375.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Gut. 2006 Apr;55(4):585-6 [16531543.001]
  • [Cites] Med Oncol. 2008;25(2):207-13 [18488160.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):316-25 [15900603.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1781-8 [16136600.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1580-2 [15735135.001]
  • [Cites] Histopathology. 2006 Jan;48(1):83-96 [16359540.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6800-1; author reply 6801-2 [16170192.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):460-4 [12888812.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5322-5 [18955449.001]
  • [Cites] Hum Pathol. 2002 May;33(5):478-83 [12094372.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):347-52 [17435539.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jan;36(1):17-24 [16418188.001]
  • (PMID = 19294538.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


8. van Buuren HR, Vleggaar FP, Willemien Erkelens G, Zondervan PE, Lesterhuis W, Van Eijck CH, Puylaert JB, Van Der Werf SD: Autoimmune pancreatocholangitis: a series of ten patients. Scand J Gastroenterol Suppl; 2006;(243):70-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical and biochemical remission occurred in three; in one other patient, previously documented intrahepatic biliary strictures had disappeared after 3 months.
  • The clinical features, pancreatic involvement, age at presentation, absence of IBD and response to steroids all plead against a diagnosis of "classical" PSC.
  • The disease has been associated with Sjögren's disease, retroperitoneal fibrosis and other fibrosing conditions, and may be a manifestation of a systemic fibro-inflammatory disorder.
  • CONCLUSION: Autoimmune pancreatocholangitis is a distinct inflammatory disorder involving the pancreas and biliary tree.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Cholangitis, Sclerosing / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Aged, 80 and over. Cholagogues and Choleretics / therapeutic use. Cholangiopancreatography, Endoscopic Retrograde. Colonoscopy. Common Bile Duct / pathology. Common Bile Duct / radiography. Common Bile Duct / ultrasonography. Diagnosis, Differential. Fibrosis / diagnosis. Fibrosis / drug therapy. Humans. Immunosuppressive Agents / therapeutic use. Liver / pathology. Liver / radiography. Liver / ultrasonography. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreatic Ducts / radiography. Pancreatic Ducts / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / drug therapy. Tomography, X-Ray Computed. Ultrasonography, Interventional. Ursodeoxycholic Acid / therapeutic use

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782625.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 0 / Immunosuppressive Agents; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


9. Tebbi CK, Mendenhall N, London WB, Williams JL, de Alarcon PA, Chauvenet AR, Children's Oncology Group: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer; 2006 Feb;46(2):198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients achieved remission after completion of therapy.
  • There have been four recurrences and a remission death due to gunshot wound.
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bleomycin / administration & dosage. Bleomycin / adverse effects. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging / methods. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Feb;46(2):122-6 [16261587.001]
  • (PMID = 16136581.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down


10. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR: Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat; 2007 May;14(5):360-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other than fibrosis, other factors independently associated with liver stiffness were ALT for all patients and chronic hepatitis patients (P < 0.001), and 12-month persistently normal ALT (biochemical remission, P < 0.001) in cirrhotics.
  • In patients with biochemical remission either spontaneous or after antiviral therapy (48 of 228, 21%), liver stiffness was lower than in patients with identical fibrosis stage, but elevated ALT (P < 0.001).

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439526.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


11. Citrome L: Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med; 2010 Jul;122(4):39-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
  • OBJECTIVE: To describe the efficacy and safety of adjunctive aripiprazole, olanzapine, and quetiapine for major depressive disorder.
  • DATA EXTRACTION: Descriptions of the principal results and calculation of number needed to treat (NNT) for response and remission and number needed to harm (NNH) for relevant dichotomous adverse outcomes were extracted.
  • DATA SYNTHESIS: Three registration studies of adjunctive aripiprazole, 5 for olanzapine-fluoxetine combination, and 2 for quetiapine extended-release reveal NNT for response and remission to range from 7 to 14 and 7 to 13, respectively, for adjunctive antipsychotic versus antidepressant monotherapy, depending on the antipsychotic and/or dose.
  • In the case of the adjunctive second-generation antipsychotics approved for treating major depressive disorder, these trade-offs vary greatly among the choices available and require careful, individualized, patient-centered clinical decision making.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Benzodiazepines / therapeutic use. Depressive Disorder, Major / drug therapy. Dibenzothiazepines / therapeutic use. Piperazines / therapeutic use. Quinolones / therapeutic use

  • Genetic Alliance. consumer health - Major depressive disorder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Olanzapine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20675970.001).
  • [ISSN] 1941-9260
  • [Journal-full-title] Postgraduate medicine
  • [ISO-abbreviation] Postgrad Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dibenzothiazepines; 0 / Drug Combinations; 0 / Piperazines; 0 / Quinolones; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; 2S3PL1B6UJ / Quetiapine Fumarate; 82VFR53I78 / Aripiprazole
  • [Number-of-references] 26
  •  go-up   go-down


12. Tan RM, Quah TC, Aung L, Liang S, Kirk RC, Yeoh AE: Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol. Pediatr Blood Cancer; 2007 Mar;48(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
  • BACKGROUND: The introduction of the United Kingdom Medical Research Council's 10th AML trial (MRC AML 10) protocol incorporating high-dose anthracycline therapy has improved outcome of children with acute myeloid leukemia (AML).
  • MRC AML 10-treated patients (n = 14) had significantly better 3-year overall, event-free, and disease-free survival (74% vs. 35%, 77% vs. 20%, 83% vs. 31%; P = 0.019, P = 0.002, and P = 0.010, respectively) and were likelier to achieve complete remission (CR) than non-MRC AML 10 patients (P = 0.102).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. 6-Mercaptopurine / adverse effects. Acute Disease. Amsacrine / administration & dosage. Amsacrine / adverse effects. Azacitidine / administration & dosage. Azacitidine / adverse effects. Child. Child, Preschool. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Developing Countries. Disease-Free Survival. Drug Evaluation. Drug-Induced Liver Injury / etiology. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Heart Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Infant. Infection / etiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Retrospective Studies. Singapore / epidemiology. Survival Analysis. Thioguanine / administration & dosage. Thioguanine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16602120.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine; M801H13NRU / Azacitidine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; MRC AML 10 protocol; POG-8498 protocol
  •  go-up   go-down


13. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood; 2005 Feb 1;105(3):973-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%).
  • Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%.
  • [MeSH-major] Leukemia / drug therapy. Leukemia / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Myelodysplastic Syndromes / pathology. Primary Myelofibrosis / pathology


14. Kawabata Y, Hirokawa M, Saitoh Y, Kosugi S, Yoshioka T, Fujishima M, Fujishima N, Kameoka Y, Saitoh H, Kume M, Takahashi N, Sawada K: Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia. Int J Hematol; 2006 Dec;84(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.
  • A 43-year-old Japanese woman underwent unrelated cord blood transplantation (CBT) during remission for acute lymphoblastic leukemia with t(4; 11)(q21;q23).
  • The posttransplantation clinical course was mostly uneventful, and the leukemia remained in remission.
  • [MeSH-major] Epstein-Barr Virus Infections. Hemorrhage. Herpesvirus 4, Human. Lymphohistiocytosis, Hemophagocytic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


15. Biondo M, Field J, Toh BH, Alderuccio F: Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis. J Pathol; 2006 Jul;209(3):384-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis.
  • Prednisolone promoted remission of gastritis in both mouse models of experimental autoimmune gastritis, evident by reduction in stomach size, clearing of gastric inflammatory infiltrate, and regeneration of the gastric mucosa.
  • It is concluded that prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis.
  • Prolonged remission of autoimmune gastritis in some athymic mice suggests a role for the thymus in disease relapse.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16710833.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Autoantibodies; 0 / Glucocorticoids; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9PHQ9Y1OLM / Prednisolone; EC 3.6.3.10 / H(+)-K(+)-Exchanging ATPase
  •  go-up   go-down


16. Mikulic M, Batinic D, Sucic M, Davidovic-Mrsic S, Dubravcic K, Nemet D, Serventi-Seiwerth R, Sertic D, Labar B: Biological features and outcome of biphenotypic acute leukemia: a case series. Hematol Oncol Stem Cell Ther; 2008 Oct-Dec;1(4):225-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological features and outcome of biphenotypic acute leukemia: a case series.
  • BACKGROUND: Biphenotypic acute leukemia (BAL) is a distinct entity that is immunophenotypically defined by the European Group for the Immunological Classification of Leukemia (EGIL) scoring system and accounts for less than 5% of all acute leukemia cases.
  • Since it is a rare and heterogeneous form of acute leukemia with an allegedly poor outcome, there is no consensus on the best treatment approach in these patients.
  • PATIENTS AND METHODS: Using the EGIL system, we identified 21 cases (3.9%) of BAL from 535 newly diagnosed acute leukemia patients in an 11-year period.
  • RESULTS: There were ten cases of myeloid+B-lymphoid leukemia, eight cases of myeloid+T-lymphoid, one case of B+T-lymphoid and two cases of trilineage (myeloid+B+T-lymphoid leukemia).
  • The complete remission (CR) rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%.
  • Patients that received acute lymphoblastic leukemia-oriented chemotherapy had a higher CR rate compared with those who received acute myeloid leukemia-oriented chemotherapy (100% vs. 60%, P = .007).
  • The white blood cell count at diagnosis was found to have statistically significant impact on survival.
  • CONCLUSION: Despite the progress in the treatment of acute leukemia, the prognosis of BAL remains poor and treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology. Leukemia, Biphenotypic, Acute / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Stem Cell Transplantation. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058478.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Jain LR, Denning DW: The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect; 2006 May;52(5):e133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Voriconazole is a useful alternative therapy for CCPA, with a response rate of 64%, over 3 months, and continuing partial remission of disease for much longer periods.

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427702.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


18. Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol; 2010 Mar;34(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of specific entities of B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which determine the optimal treatment strategy.
  • The complete remission was achieved in all seven patients.
  • Six patients are still in complete remission at least 12 months after having finished chemotherapy and one patient relapsed two months after the last cycle and subsequently died.
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. B-Lymphocytes / pathology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunophenotyping. Infusions, Intravenous. Male. Recurrence. Remission Induction. Rituximab


19. Jäger M, Riedel M, Obermeier M, Schennach-Wolff R, Seemüller F, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rüther E, Klingberg S, Gastpar M, Bottlender R, Möller HJ: Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophr Res; 2010 May;118(1-3):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions.
  • Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge.
  • Of the total sample, 78.5% achieved the criteria for response and 44.6% those for remission.
  • CONCLUSION: Response rates were comparable to those found in efficacy studies, and remission rates were slightly higher.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20181461.001).
  • [ISSN] 1573-2509
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


20. Sun Y, Wu RH, Liu WH, Huang JW: [Analysis of the dynamic change of TF, TFPI and IL-1beta in plasma of patients with acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun;16(3):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the dynamic change of TF, TFPI and IL-1beta in plasma of patients with acute leukemia].
  • All the three indications of patients were measured in different stages including pre-chemotherapy phase, at 72 hours after chemotherapy, complete remission phase.
  • 16 out of 24 patients got complete remission, there was no difference of TF, TFPI and IL-1beta between complete remission group and normal control group.
  • It is concluded that the levels of TF, TFPI and IL-1beta in plasma can be used as the indicators for understanding clinical features, evaluating disease status and predicting prognosis in acute leukemia patients.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549615.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-1beta; 0 / Lipoproteins; 0 / lipoprotein-associated coagulation inhibitor; 9035-58-9 / Thromboplastin
  •  go-up   go-down


21. El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK: Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis; 2006 Feb;29(1):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At baseline, bone pain was present in 5 patients and ERT resulted in complete symptomatic remission in all of them.
  • ERT was effective in ameliorating radiological manifestations of skeletal disease and achieving complete remission of bone pain.
  • [MeSH-minor] Adolescent. Bone and Bones / drug effects. Child. Child, Preschool. Egypt. Female. Genotype. Heterozygote. Humans. Infant. Male. Phenotype. Remission Induction. Time Factors


22. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Fukuo Y, Naitoh H, Umene-Nakano W, Inada T, Nakamura J, Ozaki N, Iwata N: SIRT1 gene is associated with major depressive disorder in the Japanese population. J Affect Disord; 2010 Oct;126(1-2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIRT1 gene is associated with major depressive disorder in the Japanese population.
  • We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks, and clinical remission as an SIGH-D score of less than 7 at 8 weeks.
  • [MeSH-major] Depressive Disorder, Major / genetics. Sirtuin 1 / genetics

  • Genetic Alliance. consumer health - Major depressive disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20451257.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1
  •  go-up   go-down


23. Krstovski N, Janić D, Dokmanović L, Brdar R: [Clinical characteristics and survival of children with langerhans cell hystiocytosis]. Srp Arh Celok Lek; 2008 Sep-Oct;136(9-10):514-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were in complete remission averagely following 162 and 82 months respectively.
  • Four patients died due to disease progression 3, 16, 36 and 66 months after diagnosis.
  • Nine patents with multisystem disease were in remission with 117 months of follow-up.
  • [MeSH-major] Histiocytosis, Langerhans-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069343.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


24. Zhang W, Fu R, Liu WH, Cheng YQ, Song WX, DU LJ, Ruan EB, Zhang LT, Wang XM, Liang Y, Wang GJ, Qu W, Song J, Zhang RL, Guan J, Li LJ, Zou P, Shao ZH: [Prognosis and related factors of acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1102-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and related factors of acute lymphoblastic leukemia].
  • In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study.
  • The therapeutic efficacy and prognosis of 53 cases of ALL were analyzed, the remission, relapse, overall survival and event-free survival were studied, and relation between different factors and prognosis of ALL were investigated by comparison of cases in same stage.
  • The results showed that the complete remission was achieved in 36 out of 53 patients, the total remission rate was 67.9%, the total relapse rate was 37.7%, the median relapse duration was 6 months after remission.
  • Median overall survival (OS) and median event-free survival (EFS) time were 4 and 1 months after remission respectively, OS and EFS rate of 18 month was 35.1% and 14.2%.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956700.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Thomann PA, Wüstenberg T, Santos VD, Bachmann S, Essig M, Schröder J: Neurological soft signs and brain morphology in first-episode schizophrenia. Psychol Med; 2009 Mar;39(3):371-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Forty-two patients, all receiving atypical neuroleptics, with first-episode schizophrenia or schizophreniform disorder and 22 healthy controls matched for age and gender were included.
  • NSS were examined on the Heidelberg Scale after remission of the acute symptoms before discharge and correlated to density values by using optimized voxel-based morphometry (VBM).
  • [MeSH-major] Brain / pathology. Nervous System Diseases / diagnosis. Schizophrenia / diagnosis. Schizophrenia / pathology. Schizophrenic Psychology
  • [MeSH-minor] Adult. Antipsychotic Agents. Female. Functional Laterality / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neurologic Examination. Psychomotor Performance / physiology. Psychotic Disorders / diagnosis. Psychotic Disorders / pathology. Severity of Illness Index

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18578894.001).
  • [ISSN] 0033-2917
  • [Journal-full-title] Psychological medicine
  • [ISO-abbreviation] Psychol Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


26. Swoger JM, Weiler CR, Arora AS: Eosinophilic esophagitis: is it all allergies? Mayo Clin Proc; 2007 Dec;82(12):1541-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eosinophilic esophagitis (EE) is an increasingly recognized disorder in the adult population, most often manifested by symptoms of dysphagia and food impaction.
  • However, new studies suggest that patch testing could add to diagnostic accuracy in EE because the disorder might not be a classic type I allergic response.
  • These diets, which have been extremely successful in reducing symptoms, have also been shown to induce histological improvement and remission.

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053464.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


27. Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess; 2009 Sep;13 Suppl 2:41-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The submitted clinical evidence included two randomised controlled trials [European Organisation for Research and Treatment of Cancer (EORTC) and German Low Grade Lymphoma Study Group - Fludarabine, Cyclophosphamide and Mitoxantrone and (GLSG-FCM)] comparing the clinical effects of chemotherapy with or without rituximab in the induction of remission at first or second relapse and the clinical benefits of rituximab maintenance therapy versus the NHS's current clinical practice of observation for follicular lymphoma (FL) patients.
  • Furthermore, rituximab maintenance therapy increased the median length of remission when compared with observation only.
  • The guidance issued by NICE as a result of the STA states that in people with relapsed stage III or IV follicular NHL, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804688.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 12
  •  go-up   go-down


28. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K: Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev; 2005;(1):CD004277
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine A for induction of remission in severe ulcerative colitis.
  • SELECTION CRITERIA: Randomised clinical trials comparing cyclosporine A with placebo or no intervention to obtain and maintain remission of idiopathic ulcerative colitis.
  • After 1 year 7/9 responders in the cyclosporine group were still in remission compared with 4/8 in the steroid group (p > 0.05) and the colectomy rate was similar in both groups.
  • [MeSH-minor] Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674937.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 54
  •  go-up   go-down


29. Ducharme J, Pelletier C, Zacharias R: The safety of infliximab infusions in the community setting. Can J Gastroenterol; 2010 May;24(5):307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infliximab, a chimeric anti-TNFalpha monoclonal antibody, has been shown to reduce the severity of symptoms or induces remission of active disease.
  • RESULTS: A total of 524 (2.5% of all infusions) acute ADRs in 353 patients (11.2%) were recorded.

  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1997 Feb 22;349(9051):521-4 [9048788.001]
  • [Cites] Gut. 1996 Nov;39(5):684-9 [9026483.001]
  • [Cites] Arthritis Rheum. 1998 Sep;41(9):1552-63 [9751087.001]
  • [Cites] Mt Sinai J Med. 2005 Jul;72(4):250-6 [16021319.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3381-90 [16258899.001]
  • [Cites] Ann Rheum Dis. 2008 Feb;67(2):189-94 [17644554.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):667-77 [18311816.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Feb 1;29(3):286-97 [19132970.001]
  • [Cites] J Drugs Dermatol. 2008 Dec;7(12):1137-46 [19137767.001]
  • [Cites] Gastroenterology. 2009 Apr;136(4):1182-97 [19249397.001]
  • [Cites] J Am Acad Dermatol. 2009 Jun;60(6):1001-17 [19344980.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):148-55 [12614731.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Cytokine. 1995 Apr;7(3):251-9 [7640345.001]
  • [Cites] Annu Rev Immunol. 1996;14:397-440 [8717520.001]
  • [CommentIn] Evid Based Nurs. 2010 Oct;13(4):107-8 [20855331.001]
  • (PMID = 20485705.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC2886572
  •  go-up   go-down


30. Lee DK, Cho YS, Hong SH, Chung WH, Ahn YC: Inflammatory pseudotumor involving the skull base: response to steroid and radiation therapy. Otolaryngol Head Neck Surg; 2006 Jul;135(1):144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On follow-up MRI, none of the patients showed complete remission of the disease.

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815200.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


31. Yamauchi T, Arai H, Taga M, Amaya N, Lee JD, Ueda T: [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid]. Rinsho Ketsueki; 2005 Mar;46(3):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].
  • Remission induction therapy was performed for a 46-year-old Japanese man with acute promyelocytic leukemia using ATRA (45 mg/m2), enocitabine (170 mg/m2, 5 days), and mitoxantrone (4 mg/m2, 3 days).
  • The normal sinus rhythm was restored 15 days thereafter, and the patient eventually reached remission.
  • [MeSH-major] Heart Block / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Drug Administration Schedule. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Pacemaker, Artificial. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447716.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 9YVR68W306 / enocitabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


32. Lama M: Carpal tunnel release in patients with negative neurophysiological examinations: clinical and surgical findings. Neurosurgery; 2009 Oct;65(4 Suppl):A171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were advised of the possibility of incomplete pain remission after surgery.

  • MedlinePlus Health Information. consumer health - Carpal Tunnel Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927063.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R: Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Breast Cancer Res Treat; 2007 Nov;106(1):105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Objective response was achieved by five patients (9.3%): one complete remission (CR) (1.9%) and four partial remissions (PR) (7.4%).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295045.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol
  •  go-up   go-down


34. Hirabayashi Y, Ishii T, Harigae H: Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int; 2010 Jun;30(8):1041-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After four doses, the remission rate was 83.8% (31/37).
  • Even in the real clinical setting, treatment with tocilizumab can rapidly induce remission in RA in a high proportion of patients and is generally safe and well tolerated.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / drug therapy

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Musculoskelet Disord. 2008;9:52 [18419803.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):987-97 [18358926.001]
  • [Cites] Mod Rheumatol. 2009;19(1):12-9 [18979150.001]
  • [Cites] J Periodontol. 2009 Apr;80(4):535-40 [19335072.001]
  • [Cites] Ann Rheum Dis. 2009 Oct;68(10):1580-4 [19019888.001]
  • [Cites] J Am Geriatr Soc. 2002 Mar;50(3):430-3 [11943036.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):851-6 [8428365.001]
  • [Cites] Ann Rheum Dis. 1998 Jun;57(6):350-6 [9771209.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2006 Jun;20(3):419-33 [16777574.001]
  • [Cites] Ann Rheum Dis. 2007 Sep;66(9):1162-7 [17485422.001]
  • [Cites] Biol Pharm Bull. 2007 Nov;30(11):2001-6 [17978466.001]
  • [Cites] Arthritis Rheum. 2007 Dec;56(12):3928-39 [18050208.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):173-9 [17905606.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3537-45 [18982160.001]
  • (PMID = 19701637.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / tocilizumab
  • [Other-IDs] NLM/ PMC2877340
  •  go-up   go-down


35. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A; 2009 Mar 3;106(9):3342-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
  • All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear.
  • Eighty patients (94.1%) entered complete remission (CR).
  • These results demonstrate the high efficacy and minimal toxicity of ATRA/ATO treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for de novo APL.
  • [MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / adverse effects. Oxides / therapeutic use. Tretinoin / adverse effects. Tretinoin / therapeutic use

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]
  • [Cites] Leuk Res. 2007 Nov;31(11):1585-7 [17416415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31 [18344322.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):547-55 [18408733.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):133-5 [18293388.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3587-90 [18703707.001]
  • [Cites] Blood. 2007 Jan 15;109(2):740-6 [16968895.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]
  • [Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):130-2 [11918543.001]
  • [Cites] Hematol J. 2001;2(5):330-40 [11920269.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1916-7; author reply 1918 [12970801.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Ai Zheng. 2004 Apr;23(4):430-4 [15087033.001]
  • [Cites] Hematol Oncol. 2004 Jun;22(2):63-71 [15468344.001]
  • [Cites] Blood. 1973 Apr;41(4):489-96 [4510926.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2826-32 [8874178.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Sci Total Environ. 1997 Sep 26;204(2):147-60 [9301099.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1447-52 [9305596.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] Bone Marrow Transplant. 1999 Aug;24(3):345-8 [10455379.001]
  • [Cites] Acta Med Scand. 1957 Nov 29;159(3):189-94 [13508085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3658-65 [16076872.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1393-9 [16728984.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1355-9 [17326049.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • (PMID = 19225113.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2651325
  •  go-up   go-down


36. Al-Ali HK, Wittekind C, Niederwieser D: [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Dtsch Med Wochenschr; 2007 Aug;132(33):1688-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
  • [Transliterated title] Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie.
  • Complete remission (CR) was achieved after six cycles of doxorubicin-bleomycin-vinblastin-dacarbazine (ABVD) and cyclophosphamid-vincristine-procarbazine-prednison (COPP) regimens.
  • Histology confirmed the initial diagnosis.
  • A partial remission was induced with two further DEXA-BEAM cycles (dexamethasone, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea], ectoposide, ara-C, melphalan).
  • A complete remission was achieved 2 months later.
  • A second treatment with rituximab yielded another complete remission which was maintained for 20 months.
  • In our patient the safety and efficacy of rituximab in relapsed CD20-positive classical HD of an MC type was demonstrated to achieve long-lasting remission.
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Lymph Nodes / pathology. Male. Melphalan / therapeutic use. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Rituximab. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713864.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol; Dexa-BEAM protocol
  •  go-up   go-down


37. Ge M, Shi D, Wu Q, Wang M, Li L: Fluctuation of circulating tumor cells in patients with lung cancer by real-time fluorescent quantitative-PCR approach before and after radiotherapy. J Cancer Res Ther; 2005 Oct-Dec;1(4):221-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to concordance between molecular response and radiological remission, assessment of the therapeutic response might be possible by serial quantitative of CTCs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998657.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


38. Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS: Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. Eur Arch Psychiatry Clin Neurosci; 2010 Oct;260(7):553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study.
  • The aim of the study was to report on the clinical utility of naturalistic adjunctive treatment with valproate (VPA) in a group of panic disorder (PD) patients with comorbid bipolar disorder (BD) or otherwise resistant to antidepressants.
  • All patients were evaluated at baseline and at least every 2 months by means of an intensive interview including semi-structured and structured instruments (SCID, Life-Up, and Panic Disorder/Agoraphobia Interview).
  • All antidepressants-resistant subjects and 31 of 35 (88.6%) patients with bipolar comorbidity achieved symptomatological remission.
  • During the observation period, 7 (58.3%) among resistant subjects and 17 (48.6%) of bipolar patients had a relapse of panic disorder after remission.
  • Survival analysis of remission durations and onset relapses for PD and Agoraphobia did not show significant differences between the two groups.
  • [MeSH-major] Antimanic Agents / therapeutic use. Bipolar Disorder / epidemiology. Panic Disorder / drug therapy. Panic Disorder / epidemiology. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Panic Disorder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Psychiatr Scand. 1997 Feb;95(2):145-52 [9065680.001]
  • [Cites] J Clin Psychiatry. 1987 Sep;48 Suppl:13-9 [2887552.001]
  • [Cites] Int Clin Psychopharmacol. 1996 Sep;11(3):203-5 [8923100.001]
  • [Cites] Epidemiol Rev. 1995;17(1):74-82 [8521948.001]
  • [Cites] Arch Gen Psychiatry. 1977 Oct;34(10):1229-35 [911222.001]
  • [Cites] Am J Psychiatry. 2002 Jan;159(1):30-5 [11772686.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:7-17 [18985288.001]
  • [Cites] J Affect Disord. 1998 Sep;50(2-3):203-13 [9858079.001]
  • [Cites] Arch Gen Psychiatry. 1987 Jun;44(6):540-8 [3579500.001]
  • [Cites] Am J Psychiatry. 2001 Mar;158(3):420-6 [11229983.001]
  • [Cites] Am J Psychiatry. 2002 Apr;159(4):592-8 [11925297.001]
  • [Cites] Arch Gen Psychiatry. 1979 May;36(5):560-5 [435016.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(2):269-73 [1678543.001]
  • [Cites] J Affect Disord. 1993 Jul;28(3):155-63 [8408978.001]
  • [Cites] J Clin Psychiatry. 1994 Apr;55(4):134-6 [8071256.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):452-7 [16917682.001]
  • [Cites] J Affect Disord. 1998 Jan;47(1-3):1-10 [9476738.001]
  • [Cites] Psychopharmacology (Berl). 1998 Apr;136(3):243-6 [9566809.001]
  • [Cites] Psychopharmacol Bull. 1987;23(1):68-73 [3602332.001]
  • [Cites] Am J Psychiatry. 1994 Apr;151(4):541-6 [8147451.001]
  • [Cites] Can J Psychiatry. 1994 Mar;39(2):91-4 [8149324.001]
  • [Cites] Biol Psychiatry. 1997 Jul 15;42(2):90-5 [9209725.001]
  • [Cites] Anxiety. 1994-1995;1(6):302-4 [9160592.001]
  • [Cites] J Clin Psychiatry. 1992 Dec;53(12):439-42 [1487472.001]
  • [Cites] Am J Psychiatry. 2000 Jun;157(6):956-62 [10831476.001]
  • [Cites] Biol Psychiatry. 1993 Apr 1;33(7):542-6 [8513040.001]
  • [Cites] Psychiatry Res. 1997 Nov 14;73(1-2):47-56 [9463838.001]
  • [Cites] Compr Psychiatry. 1996 Mar-Apr;37(2):125-33 [8654062.001]
  • [Cites] Psychiatr Clin North Am. 1999 Sep;22(3):565-83, viii [10550856.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):428-36 [16783496.001]
  • [Cites] J Clin Psychiatry. 2002 Feb;63(2):104-7 [11874209.001]
  • [Cites] Am J Psychiatry. 1987 Apr;144(4):508-9 [3565624.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2005 Feb;255(1):65-71 [15711895.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):217-21 [17287927.001]
  • [Cites] Am J Psychiatry. 1995 Feb;152(2):280-2 [7840367.001]
  • [Cites] Can J Psychiatry. 1990 Apr;35(3):248-50 [2111204.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):55-63 [18806921.001]
  • [Cites] J Affect Disord. 2002 Feb;68(1):1-23 [11869778.001]
  • [Cites] Br J Psychiatry. 1995 Oct;167(4):487-94 [8829718.001]
  • [Cites] Can J Psychiatry. 1998 Feb;43(1):73-7 [9494751.001]
  • [Cites] Br J Psychiatry. 1990 Sep;157:430-3 [2245278.001]
  • (PMID = 20238120.001).
  • [ISSN] 1433-8491
  • [Journal-full-title] European archives of psychiatry and clinical neuroscience
  • [ISO-abbreviation] Eur Arch Psychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antimanic Agents; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


39. Grassmann JP, Jungbluth P, Bullermann L, Hakimi M, Gehrmann SV, Thelen S, Betsch M, Windolf J, Wild M: [Radial nerve palsy associated with humeral shaft fractures - early exploration or expectant procedure? An analysis concerning current strategies of treatment]. Z Orthop Unfall; 2010 Dec;148(6):691-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of neurorrhaphy, a partial or complete remission was found in 87% of cases.
  • DISCUSSION: Although a primary expectant procedure is recommended in the literature due to the high spontaneous remission rate of 90%, an early exploration of the nerve is often preferred in clinical practice.

  • MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • [ErratumIn] Z Orthop Unfall. 2010 Dec;148(6):e4
  • (PMID = 20645255.001).
  • [ISSN] 1864-6743
  • [Journal-full-title] Zeitschrift für Orthopädie und Unfallchirurgie
  • [ISO-abbreviation] Z Orthop Unfall
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


40. Wang GR, Yu Z, Zhao YZ, Li ZJ, Li CH, Qian LS, Qiu LG: [Analysis of relationship between bcr-abl transcription level detected by real-time quantitative polymerase chain reaction and clinical status of CML patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug;17(4):861-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the detected results of 161 samples, there were 33 samples' values above the baseline value, in which resistance/relapse/progression (R/R/P) 13 (39.4%, 13/33), no remission (NR) 17 (51.5%, 17/33) and complete hematologic remission (CHR) 3 (9.1%, 3/33) were observed. the values of 26 samples decreased by 0 - 1 order of magnitude (0.1 < or = bcr-abl/abl % < 1), in which R/R/P 6 (23.1%, 6/26), NR 7 (26.9%, 7/26), CHR 7 (26.9%, 7/26) and cytogenetic remission (CyR) 6 (23.1%, 6/26) were observed, the values of 19 samples decreased by 1 - 2 order of magnitude (0.01 < or = bcr-abl/abl % < 0.1), in which NR 2 (10.5%, 2/19), CHR 3 (15.8%, 3/19) and CyR 14 (73.7%, 14/19) were determined.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698217.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


41. Gallagher P, Robinson LJ, Gray JM, Porter RJ, Young AH: Neurocognitive function following remission in major depressive disorder: potential objective marker of response? Aust N Z J Psychiatry; 2007 Jan;41(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive function following remission in major depressive disorder: potential objective marker of response?
  • METHOD: A neurocognitive test battery was administered to unipolar depressed (major depressive disorder, MDD) patients (aged 18-65 years) who had been medication-free for at least 6 weeks, and to healthy controls.
  • CONCLUSIONS: This preliminary report suggests that there may be distinct temporal trajectories of neurocognitive improvement following remission in MDD.
  • [MeSH-major] Brain / physiopathology. Cognition Disorders / etiology. Cognition Disorders / physiopathology. Depressive Disorder, Major / psychology
  • [MeSH-minor] Adolescent. Adult. Diagnostic and Statistical Manual of Mental Disorders. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuropsychological Tests. Paired-Associate Learning. Psychometrics. Remission Induction. Severity of Illness Index

  • Genetic Alliance. consumer health - Major depressive disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464681.001).
  • [ISSN] 0004-8674
  • [Journal-full-title] The Australian and New Zealand journal of psychiatry
  • [ISO-abbreviation] Aust N Z J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood; 2009 Apr 30;113(18):4153-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
  • Clinical risk classification is inaccurate in predicting relapse in adult patients with acute lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate chemotherapy or stem cell transplantation (SCT).
  • Of 280 registered patients (236 in remission), 34 underwent an early SCT, 60 suffered from relapse or severe toxicity, and 142 were evaluable for MRD at the end of consolidation.
  • [MeSH-major] Neoplasm, Residual / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141862.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00358072
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


43. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J: High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer; 2008 Apr 15;112(8):1754-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 2683 patients with complete baseline data, absence of hypodiploidy/chromosome 13 deletion, beta-(2)-microglobulin <3.0 mg/L, C-reactive protein <6 mg/L, albumin >or= 3.0 g/dL, and platelet count >or= 100,000/microL all were associated independently with superior OS (P< .001), event-free survival (P< .001), and duration of complete remission (P< .001).

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):4008-10 [10845942.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2247-56 [18769451.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2732-9 [12860952.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Blood. 1986 May;67(5):1298-301 [3516252.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Apr;6(2):437-49 [1582984.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Blood. 1999 Jan 1;93(1):51-4 [9864145.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):929-36 [16432076.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1021-30 [16525139.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):825-31 [16530576.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2165-72 [16772605.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):158-64 [16939489.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2276-84 [17105813.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):176-85 [17593024.001]
  • [Cites] Blood. 2007 Aug 1;110(3):827-32 [17416735.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):822-9 [11564069.001]
  • (PMID = 18300230.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055819; United States / NCI NIH HHS / CA / CA55819
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Myeloablative Agonists; 0 / Serum Albumin; 0 / beta 2-Microglobulin; 9007-41-4 / C-Reactive Protein; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS453802; NLM/ PMC3652244
  •  go-up   go-down


44. Lock J, Couturier J, Bryson S, Agras S: Predictors of dropout and remission in family therapy for adolescent anorexia nervosa in a randomized clinical trial. Int J Eat Disord; 2006 Dec;39(8):639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of dropout and remission in family therapy for adolescent anorexia nervosa in a randomized clinical trial.
  • OBJECTIVE: The purpose of this study is to explore the predictors of dropout and remission in the treatment of adolescent anorexia nervosa (AN) using family therapy.
  • Participants were classified as remitted if they obtained an ideal body weight greater than 95% and a global eating disorder Examination score within two standard deviations of community norms at the end of 12 months.
  • RESULTS: Co-morbid psychiatric disorder and being randomized to longer treatment predicted greater dropout.
  • The presence of co-morbid psychiatric disorder, being older, and problematic family behaviors led to lower rates of remission.
  • A reduction of child behavioral symptoms, a decline in problematic family behaviors, and early weight gain were all within treatment changes that increased the chance of remission.
  • CONCLUSION: Co-morbid psychiatric disorder, family behaviors, and early response to treatment are important factors when predicting dropout and remission in family therapy for adolescent AN.
  • [MeSH-minor] Adolescent. Child. Female. Humans. Male. Prospective Studies. Remission Induction

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 by Wiley Periodicals, Inc.
  • (PMID = 16927385.001).
  • [ISSN] 0276-3478
  • [Journal-full-title] The International journal of eating disorders
  • [ISO-abbreviation] Int J Eat Disord
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / K08 MH1457; United States / NIMH NIH HHS / MH / K24 MH074467
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


45. Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, Soares J Jr, Delbeke D, Topfer LA, Buccheri V, Meneghetti JC: Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol; 2010 Mar 10;28(8):1415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy.
  • PURPOSE: To assess the cost effectiveness of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with Hodgkin's lymphoma (HL) with unconfirmed complete remission (CRu) or partial remission (PR) after first-line treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142591.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Sasaki M, Sugimoto K, Isobe Y, Oshimi K: Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide. Eur J Haematol; 2008 Aug;81(2):160
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
  • [MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Middle Aged. Remission Induction. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363868.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


47. Nyenwe EA, Dagogo-Jack S: Iodine deficiency disorders in the iodine-replete environment. Am J Med Sci; 2009 Jan;337(1):37-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary iodine supplementation alone resulted in complete remission of IDD in the subjects, including the 2 patients with hypothyroidism.
  • It is pertinent that the correct diagnosis be made to avoid unwarranted life-long thyroxine therapy in patients presenting with goiter and hypothyroidism, which is easily treatable with iodized salt.
  • These cases underscore the need for considering iodine deficiency in the etiologic diagnosis of goiter and hypothyroidism, even in iodine-sufficient regions.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):14-5 [9703371.001]
  • [Cites] Afr J Med Med Sci. 1995 Sep;24(3):211-7 [8798954.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3401-8 [9768638.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):561-6 [10022416.001]
  • [Cites] Conn Med. 2005 Feb;69(2):73-7 [15779603.001]
  • [Cites] Ther Drug Monit. 2005 Apr;27(2):178-85 [15795649.001]
  • [Cites] Thyroid. 2005 Jul;15(7):692-9 [16053386.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2819-21 [16807421.001]
  • [Cites] J Nutr. 2007 Mar;137(3):573-7 [17311942.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1263-4 [17881763.001]
  • [Cites] Postgrad Med J. 2001 Apr;77(906):217-20 [11264481.001]
  • [Cites] Thyroid. 2002 Oct;12(10):867-78 [12487769.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1859-60 [14654340.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):764-70 [2921318.001]
  • [Cites] Endocr Res. 1994 Aug;20(3):247-57 [7995255.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2574-6 [7673397.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3398-400 [9768637.001]
  • (PMID = 19155752.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK067269-03; United States / NCRR NIH HHS / RR / M01 RR00211; United States / NCRR NIH HHS / RR / M01 RR000211; United States / NIDDK NIH HHS / DK / R01 DK067269; United States / NIDDK NIH HHS / DK / R01 DK067269-03
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9679TC07X4 / Iodine
  • [Other-IDs] NLM/ NIHMS85795; NLM/ PMC2634852
  •  go-up   go-down


48. Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y, All Collaborators of the IDEC-C2B8 Study Group in Japan: Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Sci; 2010 Dec;101(12):2579-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, R-CHOP is a highly effective initial treatment for untreated indolent B-NHL in terms of ORR and OS; however, its long-term PFS is not good enough either in concurrent or sequential combination, warranting further investigations on post-remission therapy.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20942866.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Investigator] Aikawa K; Nakata M; Kasai M; Kiyama Y; Kano Y; Akutsu M; Miwa A; Takesako N; Itoh K; Igarashi T; Ishizawa K; Tobinai K; Kobayashi Y; Watanabe T; Ohyashiki K; Tauchi T; Hotta T; Ando K; Ohnishi K; Morishima Y; Ogura M; Kagami Y; Kinoshita T; Murate T; Nagai H; Tsushita K; Ohashi H; Kageyama S; Yamaguchi M; Taniwaki M; Ohno H; Ishikawa T; Suzuki T; Hiraoka A; Karasuno T; Murayama T; Mizuno I; Sakai A; Uike N; Maeda T; Tsukasaki K
  •  go-up   go-down


49. Ossola M, Romani A, Tavazzi E, Pichiecchio A, Galimberti CA: Epileptic mechanisms in Charles Bonnet syndrome. Epilepsy Behav; 2010 May;18(1-2):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adjustment of antiepileptic drug treatment led to remission of the CVHs with simultaneous disappearance of PLEDs plus and epileptic seizures and return to previous neurological status.
  • [MeSH-major] Epilepsy / complications. Epilepsy / diagnosis. Hallucinations / etiology

  • Genetic Alliance. consumer health - Charles Bonnet Syndrome.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471325.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol; 2009 Jan 20;27(3):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
  • PURPOSE: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis.
  • To verify this, the Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group conducted a prospective trial.
  • PATIENTS AND METHODS: Between March 1999 and July 2005, 91 children with relapsed ALL treated according to the ALL-REZ BFM 96 or 2002 protocols and receiving stem-cell transplantation in >or= second remission were enrolled.
  • High-risk patients (S3/4, third complete remission) who received transplantation with an MRD load of less than 10(-4) leukemic cells (n = 25) showed a pEFS and CRI of 0.53 and 0.18, respectively.
  • [MeSH-major] Neoplasm, Residual / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation


51. Szymanik-Grzelak H, Sladowska J, Pańczyk-Tomaszewska M, Sekowska R, Roszkowska-Blaim M: [Voiding dysfunction in children with vesicoureteral reflux]. Przegl Lek; 2006;63 Suppl 3:142-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Kidney Diseases / complications. Kidney Diseases / physiopathology. Male. Remission Induction. Retrospective Studies. Ureteroscopy / methods


52. Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bahar AY, Giles J, Venn NC, Pozza LD, Baker DL, Marshall GM, Kees UR, Haber M, Norris MD: Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood; 2007 Jul 15;110(2):632-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone.
  • Relapse following remission induction chemotherapy remains a barrier to survival in approximately 20% of children suffering from acute lymphoblastic leukemia (ALL).
  • To investigate the mechanism of relapse, 27 matched diagnosis and relapse ALL samples were analyzed for clonal populations using polymerase chain reaction (PCR)-based detection of multiple antigen receptor gene rearrangements.
  • More sensitive clone-specific PCR revealed that, in 8 cases, these "relapse clones" were present at diagnosis and a significant relationship existed between presence of the relapse clone at diagnosis and time to first relapse (P < .007).
  • Furthermore, in cases where the relapse clone could be quantified, time to first relapse was dependent on the amount of the relapse clone at diagnosis (r = -0.84; P = .018).
  • This observation, together with demonstrated differential chemosensitivity between subclones at diagnosis, argues against therapy-induced acquired resistance as the mechanism of relapse in the informative patients.
  • [MeSH-major] Drug Resistance, Neoplasm. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


53. Llorca PM, Lançon C, Lancrenon S, Bayle FJ, Caci H, Rouillon F, Gorwood P: The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire. Schizophr Res; 2009 Sep;113(2-3):218-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire.
  • Functional remission is an important treatment goal in schizophrenia, as independent living and reintegration of patients into the community and the workplace is the ultimate goal of any treatment.
  • Nevertheless, assessing functional remission in schizophrenia is problematic, as it is a multifactorial and complex entity reflecting various aspects such as symptoms severity, personal skills and socio-cultural expectancies.
  • The purpose of this study was to create and validate a novel scale for the evaluation of functional remission in schizophrenia.
  • The "Functional Remission of General Schizophrenia" (FROGS) scale was developed using the expert consensus method following a MEDLINE and standard database search.
  • Out of the 61 initially proposed, 19 items were selected as gathering the core aspects of functional remission in schizophrenia detected in the literature.
  • The FROGS was then evaluated in 432 patients with DSM-IV criteria of schizophrenia, all of them meeting the symptomatic remission criteria of Andreasen et al. [Andreasen, N.C., Carpenter, W.T., Kane, J.M., Lasser, R.A., Marder, S.R., Weinberger, D.R., 2005.
  • Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J.
  • ' The FROGS total score can be used to measure a general construct for the evaluation of functional remission in schizophrenia..
  • [MeSH-major] Psychiatric Status Rating Scales. Schizophrenia / diagnosis. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464855.001).
  • [ISSN] 1573-2509
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Wang Q, Liu H, Zhang X, Liu Q, Xing Y, Zhou X, Tong C, Zhu P: High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood. Blood; 2010 Dec 23;116(26):5941-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms of all 5 patients improved between 3 and 10 days after the infusion; thereafter, 3 cases showed complete remission for 6-18 months without further therapy and 2 had partial remission.
  • [MeSH-minor] Adolescent. Child. Chimerism. DNA, Viral / genetics. Female. Hematopoietic Stem Cell Transplantation. Herpesvirus 4, Human / pathogenicity. Humans. Immunotherapy, Adoptive. Male. Remission Induction. Sex-Determining Region Y Protein. Transplantation, Homologous. Watchful Waiting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20926772.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / SRY protein, human; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


55. Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX: [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):435-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the clinical characteristics of adult acute lymphoblastic leukemia (ALL), compare the efficacy of different induction regimens and analyze the prognostic factors.
  • 2) 149 patients completed the VDCP, VDLP or VDCLP induction therapies (at least 4 weeks treatment for each), 140 (93.7%) of them achieved complete remission (CR) with the first course CR rates of 80.8%, 92.3% and 81.4% , respectively (P=0.618).
  • Age and WBC at diagnosis, presence of t(9;22) (q34;q11) and the courses of post-remission treatment are important prognostic factors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035173.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


56. Elkayam O, Litinsky I, Levartovsky D, Caspi D: The changing face of spondyloarthropathies under TNF α blockade. Open Rheumatol J; 2008;2:53-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infliximab induced a remission of AS, but he developed overt Crohn's disease two years after starting treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2004 May;50(5):1690-2 [15146441.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):203-6 [15269630.001]
  • [Cites] Ann Pharmacother. 2004 Jan;38(1):54-7 [14742794.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):1015-23 [12687543.001]
  • [Cites] Arthritis Res. 2002;4 Suppl 2:S34-40 [12110156.001]
  • [Cites] J Pathol. 2002 Mar;196(3):343-50 [11857499.001]
  • [Cites] Arthritis Rheum. 2001 Apr;44(4):931-9 [11315932.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):532-6 [18203308.001]
  • [Cites] Medicine (Baltimore). 2007 Jul;86(4):242-51 [17632266.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):396 [17573878.001]
  • [Cites] J Dermatol. 2007 Jul;34(7):468-72 [17584325.001]
  • [Cites] Ann Dermatol Venereol. 2007 Apr;134(4 Pt 1):363-7 [17483757.001]
  • [Cites] Eye (Lond). 2007 Apr;21(4):547-9 [16456589.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1181-95 [17127203.001]
  • [Cites] Rheumatol Int. 2006 Oct;26(12):1158-60 [16738903.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):270-2 [17310016.001]
  • [Cites] Ann Rheum Dis. 2006 Sep;65(9):1259 [16905590.001]
  • [Cites] J Rheumatol. 2006 Jul;33(7):1411-4 [16821276.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):223-31 [17310002.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):176-9 [17176269.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):438-9 [17304662.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):247-9 [17304646.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):380-5 [17013997.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):178-9 [16485887.001]
  • [Cites] Ann Rheum Dis. 2006 Mar;65(3):405-7 [16150791.001]
  • [Cites] Br J Dermatol. 2005 Dec;153(6):1243-4 [16307676.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):713-4 [16197398.001]
  • [Cites] Rheumatol Int. 2005 Sep;25(7):550-2 [15711788.001]
  • [Cites] Dig Liver Dis. 2005 Oct;37(10):761-7 [16024303.001]
  • [Cites] Arthritis Rheum. 2005 Aug;52(8):2513-8 [16052599.001]
  • [Cites] Autoimmunity. 2005 Mar;38(2):155-60 [16040336.001]
  • [Cites] Curr Opin Rheumatol. 2005 Jul;17(4):400-5 [15956835.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1333-4; author reply 1334 [15818679.001]
  • [Cites] Ann Rheum Dis. 2005 Mar;64(3):403-7 [15297281.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12):1490-5 [15611427.001]
  • [Cites] J Rheumatol. 1991 Oct;18(10):1542-51 [1765980.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):506-7 [15327565.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):439-40 [15303790.001]
  • [Cites] Curr Mol Med. 2004 Feb;4(1):31-40 [15011957.001]
  • (PMID = 19088872.001).
  • [ISSN] 1874-3129
  • [Journal-full-title] The open rheumatology journal
  • [ISO-abbreviation] Open Rheumatol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2588090
  • [Keywords] NOTNLM ; Infliximab / anti-TNFα / crohn / psoriasis / spondyloarthropathy
  •  go-up   go-down


57. Kinrys G, Wygant LE, Pardo TB, Melo M: Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry; 2006 Feb;67(2):211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levetiracetam for treatment-refractory posttraumatic stress disorder.
  • OBJECTIVE: To assess the use of levetiracetam, a novel anticonvulsant agent, in the treatment of refractory posttraumatic stress disorder (PTSD).
  • METHOD: Retrospective analysis was conducted of 23 patients with DSM-IV diagnosis of PTSD who, after being deemed partial or nonresponders to antidepressant therapy, received levetiracetam in a naturalistic fashion.
  • Thirteen patients (56%) met responder criteria at endpoint (PCL-C mean change=23.5, CGI-I score<or=2), and 6 (26%) met remission criteria (CGI-S score<or=2).

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • Hazardous Substances Data Bank. PIRACETAM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566615.001).
  • [ISSN] 0160-6689
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antidepressive Agents; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  •  go-up   go-down


58. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, van Deventer SJ, Hommes DW, Hooymans PM: Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit; 2006 Feb;28(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, mean 6-TGN concentrations did not differ in patients with active disease versus patients in remission.

  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418693.001).
  • [ISSN] 0163-4356
  • [Journal-full-title] Therapeutic drug monitoring
  • [ISO-abbreviation] Ther Drug Monit
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


59. De Castro J, Lorenzo A, Morales S, Belón J, Dorta J, Lizón J, Madroñal C, Gallurt PM, Casado E, Feliu J, Barón MG, Oncopaz Cooperative Group: Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol; 2005 Feb;55(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 46 patients assessed for response, 12 (26%) had a partial remission (95% CI 13-39%).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15322824.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


60. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE: The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum; 2005 Jun;34(6):819-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The only TNF-blocker currently approved for the induction and maintenance of remission in CD is infliximab.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942917.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  • [Number-of-references] 116
  •  go-up   go-down


61. Coruzzi P, Castiglioni P, Parati G, Brambilla V, Brambilla L, Gualerzi M, Cademartiri F, Franzè A, De Angelis G, Di Rienzo M, Di Mario F: Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn's disease. Eur J Clin Invest; 2007 Dec;37(12):964-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was thus to explore the features of cardiovascular autonomic regulation in ulcerative colitis and Crohn's disease during their remission phase.


62. Zunker C, Peterson CB, Cao L, Mitchell JE, Wonderlich SA, Crow S, Crosby RD: A receiver operator characteristics analysis of treatment outcome in binge eating disorder to identify patterns of rapid response. Behav Res Ther; 2010 Dec;48(12):1227-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A receiver operator characteristics analysis of treatment outcome in binge eating disorder to identify patterns of rapid response.
  • The purpose of this study was to perform a receiver operator characteristics (ROC) analysis on a treatment sample from a randomized controlled treatment trial of participants with binge eating disorder (BED).
  • Participants who demonstrated a 15% reduction in binge eating episodes at week one were more likely to respond positively to treatment and achieve clinical remission.
  • Findings from the current study suggest that a significant reduction in binge eating during the first week of treatment may be predictive of end of treatment remission in those with BED.
  • [MeSH-major] Binge-Eating Disorder / therapy. Cognitive Therapy / methods. ROC Curve

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Am J Psychiatry. 2004 Dec;161(12):2322-4 [15569910.001]
  • [Cites] Int J Eat Disord. 2009 Apr;42(3):222-7 [18951452.001]
  • [Cites] Am J Psychiatry. 2000 Aug;157(8):1302-8 [10910795.001]
  • [Cites] Behav Res Ther. 2007 Nov;45(11):2537-50 [17659254.001]
  • [Cites] Am J Psychiatry. 2009 Dec;166(12):1347-54 [19884223.001]
  • [Cites] J Consult Clin Psychol. 2006 Jun;74(3):602-13 [16822116.001]
  • [Cites] Am J Psychiatry. 2006 Dec;163(12):2181-3 [17151172.001]
  • [Cites] Int J Eat Disord. 2010 Apr;43(3):205-17 [19402028.001]
  • [Cites] Annu Rev Clin Psychol. 2008;4:305-24 [18370619.001]
  • [Cites] Am Psychol. 2007 Apr;62(3):199-216 [17469898.001]
  • [Cites] Psychol Med. 1996 May;26(3):477-86 [8733206.001]
  • [Cites] J Consult Clin Psychol. 2007 Aug;75(4):639-44 [17663617.001]
  • (PMID = 20869041.001).
  • [ISSN] 1873-622X
  • [Journal-full-title] Behaviour research and therapy
  • [ISO-abbreviation] Behav Res Ther
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK050456; United States / NIMH NIH HHS / MH / R01 MH059674; United States / NIMH NIH HHS / MH / R13 MH081447; United States / NIMH NIH HHS / MH / R34 MH077571
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


63. Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R: Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med; 2009 Jun;34(6):355-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic response and disease remission were assessed in patients with PET/CT and clinical follow-up studies.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487844.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Lincoln TM, Ziegler M, Mehl S, Rief W: The jumping to conclusions bias in delusions: specificity and changeability. J Abnorm Psychol; 2010 Feb;119(1):40-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-one patients with schizophrenia spectrum disorders and either acute or remitted delusions and 68 healthy controls were included.
  • Participants with current delusional symptoms took fewer draws to decision (DTD) than did those in remission and healthy controls.
  • [MeSH-minor] Adult. Cognition Disorders / diagnosis. Cognition Disorders / epidemiology. Diagnostic and Statistical Manual of Mental Disorders. Female. Humans. Male. Neuropsychological Tests. Schizophrenia / diagnosis. Schizophrenia / epidemiology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141241.001).
  • [ISSN] 1939-1846
  • [Journal-full-title] Journal of abnormal psychology
  • [ISO-abbreviation] J Abnorm Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Muljono A, Graf NS, Arbuckle S: Primary cutaneous lymphoblastic lymphoma in children: series of eight cases with review of the literature. Pathology; 2009;41(3):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous lymphoblastic lymphoma in children: series of eight cases with review of the literature.
  • AIM: Primary cutaneous lymphoblastic lymphoma is a rare but well recognised tumour predominantly of childhood.
  • In this study we examine eight cases of cutaneous lymphoblastic lymphoma in children, which is the largest series to date of tumours confined to the skin with or without local lymph nodes (stage I or II) but without systemic disease at diagnosis.
  • METHODS: The clinical history and histology from the eight cases were reviewed together with a panel of immunohistochemical stains to confirm lineage and diagnosis.
  • RESULTS: Seven of the eight cases were confirmed as B-lymphoblastic lymphoma (B-LBL) of the skin, with the eighth case representing a CD4+/CD56+ plasmacytoid dendritic cell tumour.
  • The cases were all stage I or II, and all patients received systemic chemotherapy after full staging investigations to exclude systemic disease at diagnosis.
  • All patients remained in complete remission at the time of last follow-up of between 3 and 9 years from diagnosis.
  • CONCLUSIONS: Lymphoblastic lymphoma may present primarily in the skin without systemic manifestation, with the majority of such cases representing B-LBL.
  • Full staging investigations are mandatory at diagnosis to exclude systemic disease.
  • Cases confined to stage I or II at diagnosis carry an excellent prognosis with appropriate systemic chemotherapeutic treatment.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin Diseases / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291533.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 24
  •  go-up   go-down


66. Hofmann BM, Fahlbusch R: Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res; 2006;34:158-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Remission was achieved in 75.0% and recurrence was observed in 4.8% of the patients.
  • In the literature, the rates of intraoperative confirmation of an adenoma vary between 59.1 and 100%, remission rates between 42 and 100%, and recurrence rates between 3.0 and 63.2% depending on the experience of the surgeon and on the definition of remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474220.001).
  • [ISSN] 0301-3073
  • [Journal-full-title] Frontiers of hormone research
  • [ISO-abbreviation] Front Horm Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Solak Y, Atalay H, Anil M, Aydogdu I, Tonbul HZ: Cost of paid transplantation abroad: possible donor-origin early multiple myeloma in a renal transplant recipient treated using bortezomib. Transplant Proc; 2010 Sep;42(7):2813-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplantation lymphoproliferative disorder (PTLD) is the second most common cancer in these patients.
  • Although bortezomib plus dexamethasone therapy resulted in hematologic remission, the patient remained dialysis-dependent.


68. Tan E, Kuper-Hommel M, Rademaker M: Annular erythema as a sign of recurrent breast cancer. Australas J Dermatol; 2010 May;51(2):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All women were in remission from their breast cancer for at least 6 months.
  • These cases highlight the importance of recognizing this entity in the oncologic patient, where prompt skin biopsies can confirm the diagnosis and allow early initiation of therapy.
  • [MeSH-minor] Aged. Biopsy. Dermatitis / diagnosis. Diagnosis, Differential. Female. Humans. Lupus Erythematosus, Cutaneous / diagnosis. Middle Aged. Skin / pathology. Tinea / diagnosis


69. Takashima S, Numata A, Miyamoto T, Shirakawa T, Kinoshita R, Kato K, Takenaka K, Harada N, Nagafuji K, Taniguchi S, Harada M: [Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation]. Rinsho Ketsueki; 2006 Oct;47(10):1372-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation].
  • A 42-year-old woman was referred to us for the treatment of relapsed Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), which had been maintained in complete remission for seven years after an allogeneic bone marrow transplantation (allo-BMT) from an unrelated donor.
  • She received remission-reinduction chemotherapy combined with imatinib mesylate.
  • After the documentation of the molecular remission of Ph+ALL, she underwent the second allo-BMT from another unrelated donor.
  • [MeSH-major] Bone Marrow Transplantation. Calcineurin / adverse effects. Calcineurin Inhibitors. Complex Regional Pain Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


70. Consolazio A, Alò PL, Rivera M, Iacopini F, Paoluzi OA, Crispino P, Pica R, Paoluzi P: Overexpression of fatty acid synthase in ulcerative colitis. Am J Clin Pathol; 2006 Jul;126(1):113-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three groups of patients were selected: 30 with active ulcerative colitis, 30 with ulcerative colitis in remission, and 30 undergoing colonoscopy for colorectal cancer screening, as healthy control subjects.

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753600.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


71. Rubio-Tapia A, Martínez-Salgado J, García-Leiva J, Martínez-Benítez B, Uribe M: Microscopic colitides: a single center experience in Mexico. Int J Colorectal Dis; 2007 Sep;22(9):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age at diagnosis was 56.5 +/- 15.7 (range, 26-85) years.
  • More than 80% of the treated patients improved or had clinical remission.

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):225-7 [11246349.001]
  • [Cites] Am J Gastroenterol. 1995 Sep;90(9):1394-400 [7661156.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2829-33 [12425555.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):860-70 [15626904.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):878-96 [10763932.001]
  • [Cites] Dig Dis Sci. 2002 May;47(5):1122-8 [12018911.001]
  • [Cites] Curr Opin Gastroenterol. 2004 Jan;20(1):27-31 [15703617.001]
  • [Cites] J Clin Gastroenterol. 2004 May-Jun;38(5 Suppl 1):S18-26 [15115925.001]
  • [Cites] J Clin Gastroenterol. 1996 Jan;22(1):11-5 [8776087.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1974-82 [10950045.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):794-802 [12003412.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):418-23 [10022639.001]
  • [Cites] Gut. 2004 Apr;53(4):536-41 [15016748.001]
  • [Cites] Gut. 2003 Feb;52(2):248-51 [12524408.001]
  • [Cites] Rev Gastroenterol Mex. 2002 Jan-Mar;67(1):47-52 [12066432.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Mar;17(3):236-48 [11982692.001]
  • [Cites] Gut. 2004 Mar;53(3):346-50 [14960513.001]
  • [Cites] Gut. 1995 Nov;37(5):708-11 [8549950.001]
  • [Cites] J Clin Gastroenterol. 2004 May-Jun;38(5 Suppl 1):S27-30 [15115926.001]
  • [Cites] Gut. 1992 May;33(5):683-6 [1612488.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):29-36 [9428215.001]
  • [Cites] J Gastroenterol Hepatol. 2003 May;18(5):602-3 [12702056.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):606-10 [12825868.001]
  • [Cites] Gut. 1994 Mar;35(3):426-8 [8150360.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2908-13 [12425567.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1351-5 [15761974.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Mar;31(1):293-305 [12122739.001]
  • [Cites] Am J Gastroenterol. 2002 May;97(5):1164-8 [12014722.001]
  • [Cites] Gastroenterology. 2001 May;120(6):1483-4 [11313319.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1199-204 [12439114.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):245-9 [10777181.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Aug 15;22(4):277-84 [16097993.001]
  • (PMID = 17242940.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salvage surgery was performed in 13 of 21 (62%) patients; of these patients, 5 (38%) achieved long-term, complete remission after salvage surgery (median follow-up, 5.2 years; range, 3.9-8.8 years).


73. Papadopoulos VP, Vlachos O, Isidoriou E, Kasmeridis C, Pappa Z, Goutzouvelidis A, Filippou F: A gastroenteritis outbreak due to Norovirus infection in Xanthi, Northern Greece: management and public health consequences. J Gastrointestin Liver Dis; 2006 Mar;15(1):27-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • People were advised to consume bottled water and to wash their hands carefully especially after toilet use until the remission of the outbreak.

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • MedlinePlus Health Information. consumer health - Norovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680229.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


74. Kapral T, Dernoschnig F, Machold KP, Stamm T, Schoels M, Smolen JS, Aletaha D: Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther; 2007;9(4):R72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
  • Current treatment strategies aim to achieve clinical remission in order to prevent the long-term consequences of rheumatoid arthritis (RA).
  • Several composite indices are available to assess remission.
  • The aim of the present study was to determine the relevance of excluding joints of the ankles and feet in the assessment of RA disease activity and remission.
  • Thus, the difference in the joint count was not relevant for composite disease activity assessment. (c) The disease activity score based on 28 joints (DAS28) may reach levels higher than 2.6 in patients with feet swelling since these patients often have other findings that raise DAS28. (d) The frequency of remission did not change when the 28-JC was replaced by 32-JC in the composite indices. (e) The changes in joint activity over time were almost identical in longitudinal analysis.
  • [MeSH-minor] Female. Health Status. Humans. Male. Middle Aged. Outpatients. Predictive Value of Tests. Remission Induction. Surveys and Questionnaires. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2000 Jun;39(6):655-65 [10888712.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):637-41 [16219709.001]
  • [Cites] J Rheumatol. 2002 Aug;29(8):1631-8 [12180721.001]
  • [Cites] Rheumatology (Oxford). 2002 Dec;41(12):1367-74 [12468815.001]
  • [Cites] Rheumatology (Oxford). 2003 Feb;42(2):244-57 [12595618.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):36-42 [14730597.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2591-602 [15201416.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1269-75 [15361385.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1252-5 [15238643.001]
  • [Cites] Q J Med. 1968 Jul;37(147):393-406 [4877784.001]
  • [Cites] Arthritis Rheum. 1980 Feb;23(2):137-45 [7362664.001]
  • [Cites] Arthritis Rheum. 1982 May;25(5):540-9 [7044386.001]
  • [Cites] Br J Rheumatol. 1985 Feb;24(1):31-9 [3978364.001]
  • [Cites] Arthritis Rheum. 1985 Jun;28(6):613-9 [3924059.001]
  • [Cites] Arthritis Rheum. 1988 Jan;31(1):44-51 [3345231.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Baillieres Clin Rheumatol. 1992 Feb;6(1):161-91 [1563035.001]
  • [Cites] Arthritis Rheum. 1994 Apr;37(4):470-5 [8147923.001]
  • [Cites] Arthritis Rheum. 1995 Jan;38(1):38-43 [7818569.001]
  • [Cites] Arthritis Rheum. 1995 Jan;38(1):44-8 [7818570.001]
  • [Cites] Ann Rheum Dis. 1995 Dec;54(12):944-7 [8546524.001]
  • [Cites] Lancet. 1999 Jan 23;353(9149):259-66 [9929017.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):44-51 [15271770.001]
  • [Cites] Rheumatology (Oxford). 2005 Apr;44(4):472-8 [15598707.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2625-36 [16142705.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1410-3 [15941836.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64(11):1582-7 [15860509.001]
  • [Cites] Rheum Dis Clin North Am. 2006 Feb;32(1):9-44, vii [16504819.001]
  • [Cites] Arthritis Rheum. 2002 Apr 15;47(2):181-8 [11954012.001]
  • (PMID = 17662115.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Other-IDs] NLM/ PMC2206375
  •  go-up   go-down


75. Zerbib F, Thétiot V, Richy F, Benajah DA, Message L, Lamouliatte H: Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol; 2006 Apr;101(4):692-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: In esophageal achalasia, pneumatic dilations (PD) provide short-term and long-term remission rates of 60-90% and 40-50%, respectively.
  • PD were performed until remission was achieved (symptom score < or = 3, each item < 2) and subsequently when symptomatic recurrence occurred.
  • RESULTS: Initial remission was achieved in 137 of 150 (91.3%) patients with 2.67 +/- 1.59 dilations [range 1-12].
  • After initial remission, 48 of 137 (35%) patients had recurrent symptoms; the probability to be in remission at 5 and 10 yr was 67% and 50%, respectively.
  • 2-144) 108 of 137 (78.8%) patients were in remission.
  • Among 112 patients whose symptoms could be treated by repeated PD (per protocol analysis), 108 (96.4%) were in remission (3.5 +/- 2.1 PD, ext. 2-12).
  • In this group, the probability of being in remission after repeated PD at 5 and 10 yr was 96.8% and 93.4%, respectively.
  • No pretherapeutic factor influenced long-term remission rate.
  • Long-term remission can be achieved in virtually all the patients treated by repeated PD according to an "on-demand" strategy based on symptom recurrence.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retreatment

  • Genetic Alliance. consumer health - Achalasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 Apr;101(4):698-700 [16635217.001]
  • [CommentIn] Am J Gastroenterol. 2006 Oct;101(10):2441-2 [17032214.001]
  • (PMID = 16635216.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC: Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer; 2008 Nov 1;113(9):2539-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival was calculated from the time of diagnosis of brain metastases.
  • The median survival of renal cancer patients from the diagnosis of brain metastases was 10.1 months (95% confidence interval, 6.4-14.8 months).
  • Survival beyond 3 years from the time of diagnosis of brain metastases was achievable in 16% of patients and was associated with the use of systemic immunotherapy with interleukin-2 and interferon but not antiangiogenic agents.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / secondary. Kidney Neoplasms / surgery. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780316.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


77. Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol; 2009 Jun;55(6):1430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Discontinuation of treatment with tyrosine kinase inhibitors (TKIs) and readministration in case of recurrence could improve quality of life (QoL) and reduce treatment costs for patients with metastatic renal cell carcinoma (mRCC) in which a complete remission (CR) is achieved by medical treatment alone or with additional resection of residual metastases.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1439 [18950935.001]
  • (PMID = 18950936.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


78. Zheng JF, Qiu HY, Pan JL, Cen JN, Wu YF, Zhang J, Wu DP, Xue YQ: [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.]. Zhonghua Xue Ye Xue Za Zhi; 2010 Jan;31(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.].
  • OBJECTIVE: To explore the morphology, immunophenotype, cytogenetics and clinical features of TCF3-PBX1 fusion gene positive adult acute lymphoblastic leukemia (ALL).
  • Of 18 patients received chemotherapy, 17 (94.7%) achieved complete remission (CR); the median relapse-free survival (RFS) and median overall survival was 3.2 months and 7.2 months, respectively.
  • CONCLUSIONS: TCF3-PBX1-positive adult ALL had unique clinical and pathological features with high remission rate, high relapse rate and short survival time and should be considered to receive intensified treatment strategies. iFISH combined with CC and RT-PCR can increase the detection rate of t(1;19)/TCF3-PBX1 fusion gene.
  • [MeSH-major] Oncogene Proteins, Fusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302770.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


79. Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P: Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore); 2009 Nov;88(6):341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal biopsies and extensive searches for lymphoproliferative disorder were performed in all patients at presentation.
  • Initial renal remission was observed in 94% of patients.
  • Three patients with essential MC developed B-cell lymphoma 36-48 months after the diagnosis of MC.

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910748.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


80. Baharvand M, Sarrafi M, Alavi K, Jalali Moghaddam E: Efficacy of topical phenytoin on chemotherapy-induced oral mucositis; a pilot study. Daru; 2010;18(1):46-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The average time for complete remission of mucositis in phenytoin-treated group was less than that of the placebo group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22615593.001).
  • [ISSN] 1560-8115
  • [Journal-full-title] Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
  • [ISO-abbreviation] Daru
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3232086
  • [Keywords] NOTNLM ; Chemotherapy / Mucositis / Phenytoin
  •  go-up   go-down


81. Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW: A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Ann Hematol; 2006 May;85(5):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
  • In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), we combined theophylline, pentostatin, and chlorambucil at two dose levels (cohort I: 30 mg/m(2); cohort II: 20 mg/m(2)) on a 21-day cycle for up to six courses.
  • Because of myelotoxicity, this dose level defined the MTD, and de-escalation occurred.
  • An RR of 47% and a complete remission (CR) of 5% were observed for the entire group, although responses and TTP varied greatly by histology.
  • Both FL patients responded (one with partial remission and one with CR), with a 22.5-monthly median TTP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chlorambucil / administration & dosage. Chlorambucil / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Pentostatin / administration & dosage. Pentostatin / adverse effects. Recurrence. Remission Induction. Survival Rate. Theophylline / administration & dosage. Theophylline / adverse effects

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518606.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 395575MZO7 / Pentostatin; C137DTR5RG / Theophylline
  •  go-up   go-down


82. Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J, Mortensen SA: Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant; 2005 Mar;24(3):296-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
  • We compared the safety and efficacy of daclizumab and anti-thymocyte globulin (ATG) with respect to the frequency and severity of acute cardiac allograft rejection in heart transplant recipients.
  • During the induction period, defined as the first 3 months, 12 acute rejection episodes requiring treatment (ISHLT Grade > or =2) occurred in the ATG group and 9 in the daclizumab group (p > 0.05).
  • CONCLUSIONS: ATG and daclizumab are equally effective in preventing acute rejections requiring treatment (ISHLT Grade > or =2).
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Cyclosporine / blood. Female. Graft Rejection. Humans. Length of Stay. Male. Middle Aged. Postoperative Period. Remission Induction. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737756.001).
  • [ISSN] 1053-2498
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antilymphocyte Serum; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; CUJ2MVI71Y / daclizumab
  •  go-up   go-down


83. Kobak S, Oksel F, Kabasakal Y, Doganavsargil E: Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol; 2007 Dec;26(12):2191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis.


84. Yamane A, Tsukamoto N, Saitoh T, Uchiumi H, Handa H, Karasawa M, Nojima Y, Murakami H: Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern Med; 2009;48(18):1691-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney.
  • Although all-trans retinoic acid (ATRA) is widely used in acute promyelocytic leukemia (APL), there is little data as to whether or not ATRA is useful for patients with liver and renal failure.
  • With three courses of chemotherapy, complete remission has been maintained for four years in this patient.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Liver Cirrhosis / complications. Polycystic Kidney Diseases / complications. Tretinoin / therapeutic use
  • [MeSH-minor] Humans. Hypercalcemia / blood. Hypercalcemia / complications. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / complications. Liver Failure / blood. Liver Failure / complications. Male. Middle Aged. Remission Induction


85. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD: Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer; 2006 May 15;106(10):2158-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
  • BACKGROUND: The safety and efficacy of the interleukin-2 diphtheria toxin fusion protein (DAB(389)IL2; denileukin diftitox) directed against the IL-2 receptor (IL-2R) was tested in patients with recurrent or refractory chronic lymphocytic leukemia (CLL).
  • Bone marrow biopsies before and after treatment confirmed a complete remission that lasted for 1 year in 1 patient.
  • Overall, denileukin diftitox produced complete remission in 1 of 22 patients (4%) and partial remission in 5 of 22 patients (23%) for a total remission rate of 27%.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Diphtheria Toxin / administration & dosage. Interleukin-2 / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Salvage Therapy


86. Soufflet V, Van de Bruaene A, Troost E, Gewillig M, Moons P, Post MC, Budts W: Behavior of unrepaired perimembranous ventricular septal defect in young adults. Am J Cardiol; 2010 Feb 1;105(3):404-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Cardiac Catheterization. Cardiac Surgical Procedures / methods. Cohort Studies. Defibrillators, Implantable. Disease Progression. Electrocardiography. Female. Follow-Up Studies. Heart Failure / etiology. Heart Failure / physiopathology. Heart-Assist Devices. Humans. Male. Medical Records. Pacemaker, Artificial. Remission, Spontaneous. Severity of Illness Index. Stroke Volume. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20102957.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Pérez-Blanco M, Hernández Valles R, García-Humbría L, Yegres F: Chromoblastomycosis in children and adolescents in the endemic area of the Falcón State, Venezuela. Med Mycol; 2006 Aug;44(5):467-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete clinical and mycological remission was achieved in 17/20 (85%) of the patients treated with 5-FC, ajoene and electrodesiccation and/or fulguration.
  • These cases emphasize the importance of early diagnosis in difficult-to-treat mycotic diseases such as CBM.
  • [MeSH-minor] Administration, Oral. Administration, Topical. Adolescent. Adult. Antifungal Agents / therapeutic use. Ascomycota / isolation & purification. Child. Child, Preschool. Disulfides / therapeutic use. Electrocoagulation. Female. Fluorouracil / therapeutic use. Gels / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Itraconazole / therapeutic use. Male. Remission Induction. Treatment Outcome. Venezuela

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882614.001).
  • [ISSN] 1369-3786
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Disulfides; 0 / Gels; 0 / Immunosuppressive Agents; 304NUG5GF4 / Itraconazole; 99A0041VG8 / ajoene; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia; 2007 Jun;21(6):1183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
  • Here, we report on seven FIP1L1-PDGFRA-positive patients who presented with acute myeloid leukemia (AML, n=5) or lymphoblastic T-cell non-Hodgkin-lymphoma (n=2) in conjunction with AML or Eos-MPD.
  • Patients were treated with imatinib (100 mg, n=5; 400 mg, n=2) either as monotherapy (n=2), as maintenance treatment after intensive chemotherapy (n=3) or in overt relapse 43 and 72 months, respectively, after primary diagnosis and treatment of FIP1L1-PDGFRA-positive disease (n=2).
  • All patients are alive, disease-free and in complete hematologic and complete molecular remission after a median time of 20 months (range, 9-36) on imatinib.
  • The median time to achievement of complete molecular remission was 6 months (range, 1-14).
  • [MeSH-major] Eosinophilia / drug therapy. Leukemia, Myeloid / drug therapy. Oncogene Proteins, Fusion / analysis. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Receptor, Platelet-Derived Growth Factor alpha. mRNA Cleavage and Polyadenylation Factors
  • [MeSH-minor] Acute Disease. Adult. Aged. Benzamides. Disease-Free Survival. Humans. Imatinib Mesylate. Male. Middle Aged. Myeloproliferative Disorders / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction / methods


89. Ferreri AJ, Ponzoni M, Viale E, Guidoboni M, Conciliis CD, Resti AG, Politi L, Lettini AA, Sacchetti F, Dognini G, Dolcetti R, Doglioni C: Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematol Oncol; 2006 Mar;24(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cps-eradicating antibiotic therapy with doxycycline induces lymphoma remission irrespectively of the persistence of Hp infection.


90. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X: Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer; 2008 Feb 1;112(3):572-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
  • BACKGROUND: The poor prognosis for elderly patients with acute myeloid leukemia (AML) raises questions regarding the benefit of treating them with intensive chemotherapy.
  • Complete remission was obtained in 157 patients (58%).
  • By using 2 simple parameters assessed at the time of diagnosis, the authors devised a prognostic system of immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, CD15 / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085638.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


91. Shemen LJ, Shnayder Y: Office-based intralesional cidofovir injections for nasal septal papilloma: a pilot study. Otolaryngol Head Neck Surg; 2006 Jul;135(1):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All patients achieved disease remission sustained over 10 to 24 months.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815201.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


92. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, Litzow MR, Schroeter AL: Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol; 2005 Oct;141(10):1277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Scleromyxedema is a rare chronic fibromucinous disorder that can have devastating clinical manifestations, including sclerosis of the skin with progressive pharyngeal and upper airway involvement, resulting in high mortality due to respiratory complications.
  • CONCLUSIONS: High-dose chemotherapy with stem cell rescue is feasible for patients with scleromyxedema and, although not curative, offers durable remission in most patients.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Hematopoietic Stem Cell Mobilization. Humans. Lichenoid Eruptions / surgery. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Melphalan / therapeutic use. Middle Aged. Remission Induction. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Scleromyxedema.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230566.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q41OR9510P / Melphalan
  •  go-up   go-down


93. Prescot AP, Dzik-Jurasz AS, Leach MO, Sirohi B, Powles R, Collins DJ: Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia. J Magn Reson Imaging; 2005 Oct;22(4):541-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia.
  • Localized 2D 1H-MRS data were obtained from the bone marrow of healthy controls (N = 6), patients presenting with acute leukemia (N = 6) and patients with acute leukemia in remission (N = 4).
  • [MeSH-major] Bone Marrow / chemistry. Leukemia / metabolism. Lipids / analysis. Magnetic Resonance Spectroscopy / methods. Tibia / metabolism
  • [MeSH-minor] Acute Disease. Adult. Female. Humans. Male. Middle Aged. Phantoms, Imaging

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161078.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


94. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K: Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol; 2007 Jun;34(6):1353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with etanercept 25 mg twice weekly was followed by remission of the joint inflammation and improvement of the exanthem.


95. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A: Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant; 2008 Feb;41(4):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NRM was 42%, predominantly due to acute GVHD.
  • Zevalin-RIC is feasible with consistent engraftment, acceptable organ toxicity, but high rates of acute GVHD.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radioimmunotherapy / methods. Remission Induction. Transplantation, Homologous. omega-Conotoxin GVIA

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026153.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Myeloablative Agonists; 0 / ibritumomab tiuxetan; 92078-76-7 / omega-Conotoxin GVIA
  •  go-up   go-down


96. Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S: Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol Oncol Stem Cell Ther; 2010;3(3):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
  • Currently, treatment of childhood acute lymphoblastic leukemia (ALL) includes cytarabine, especially in high-risk patients.
  • PATIENTS AND METHODS: We included children diagnosed with ALL and lymphoblastic lymphoma (LL) stage III and IV.
  • Cytarabine was used during induction remission (low-dose cytarabine) and reinduction II (high-dose cytarabine) phases.
  • The median age at diagnosis was 5.8 years (range, 0.4-15 years).
  • [MeSH-major] Cytarabine / therapeutic use. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Alleles. Antigens, CD19 / metabolism. Antigens, CD45 / metabolism. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Flow Cytometry. Gene Frequency. Genotype. Humans. Infant. Male. Mucositis / chemically induced. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Neoplasm, Residual / metabolism. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890066.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


97. Bossowski AT, Reddy V, Perry LA, Johnston LB, Banerjee K, Blair JC, Savage MO: Clinical and endocrine features and long-term outcome of Graves' disease in early childhood. J Endocrinol Invest; 2007 May;30(5):388-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At diagnosis, all patients had weight loss, hyperkinetic activity, tachycardia, difficulty sleeping, and poor concentration and 11 presented with proptosis.
  • At diagnosis, height was increased with median (range) height; 1.25 standard deviation score (SDS) (-0.2-5.24) and body mass index (BMI) was decreased; -0.48 SDS (-1.65-1.26).
  • In conclusion, disturbance of growth, behavioral difficulties and infrequent spontaneous remission are key features of Graves' disease in early childhood.
  • [MeSH-minor] Age of Onset. Antithyroid Agents / administration & dosage. Attention Deficit Disorder with Hyperactivity / etiology. Carbimazole / administration & dosage. Child. Child, Preschool. Exophthalmos / etiology. Female. Growth Disorders / etiology. Humans. Hyperkinesis / etiology. Iodide Peroxidase / immunology. Male. Propylthiouracil / administration & dosage. Recurrence. Retrospective Studies. Sleep Wake Disorders / etiology. Tachycardia / etiology. Thyrotropin / blood. Thyroxine / blood. Weight Loss

  • Genetic Alliance. consumer health - Graves' Disease.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. PROPYL THIOURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Endocrinol Invest. 2008 Jun;31(6):582 [18591895.001]
  • [Cites] Arch Dis Child. 2004 Aug;89(8):745-50 [15269076.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Jan;72(1):108-15 [1986009.001]
  • [Cites] J Pediatr Endocrinol Metab. 2005 Dec;18(12):1365-72 [16459462.001]
  • [Cites] J Paediatr Child Health. 2001 Apr;37(2):176-82 [11328475.001]
  • [Cites] Thyroid. 1997 Oct;7(5):755-60 [9349579.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001;14 Suppl 5:1277-82; discussion 1297-8 [11964023.001]
  • [Cites] Pediatr Endocrinol Rev. 2005 Sep;3(1):20-32 [16369210.001]
  • [Cites] Acta Paediatr Taiwan. 2003 Jul-Aug;44(4):220-6 [14674226.001]
  • [Cites] CMAJ. 2003 Jul 22;169(2):104-5 [12874154.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3678-82 [11061522.001]
  • [Cites] Bone. 2002 Oct;31(4):457-64 [12398940.001]
  • [Cites] Expert Rev Neurother. 2002 Sep;2(5):709-16 [19810987.001]
  • [Cites] Thyroid. 1999 Sep;9(9):871-7 [10524565.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3767-76 [9814445.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):192-4 [10207926.001]
  • [Cites] Pediatr Endocrinol Rev. 2003 Dec;1 Suppl 2:212-21; discussion 221-2 [16444161.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Dec;16(9):1249-55 [14714747.001]
  • [Cites] Arch Dis Child. 1995 Jul;73(1):17-24 [7639543.001]
  • [Cites] Dis Mon. 1997 Sep;43(9):601-77 [9301645.001]
  • [Cites] Horm Res. 2005;64(4):189-97 [16220002.001]
  • [Cites] Ann Hum Biol. 2002 Jan-Feb;29(1):1-10 [11822481.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Mar;14(3):229-43 [11308041.001]
  • [Cites] Endocrinol Metab Clin North Am. 1998 Mar;27(1):109-26 [9534032.001]
  • [Cites] Eur J Endocrinol. 1994 Jun;130(6):565-8 [8205255.001]
  • (PMID = 17598970.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antithyroid Agents; 721M9407IY / Propylthiouracil; 8KQ660G60G / Carbimazole; 9002-71-5 / Thyrotropin; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


98. Murakami M, Mushiake S, Kashiwagi H, Etani Y, Miyoshi Y, Ozono K: A case of persistent hyperinsulinemic hypoglycemia of infancy successfully managed with subcutaneous octreotide injection and nocturnal intravenous glucose supply. Clin Pediatr Endocrinol; 2007;16(3):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient exhibited natural remission of hyperinsulinism with age, and all treatment was ceased at the age of 4 yr.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24790349.001).
  • [ISSN] 0918-5739
  • [Journal-full-title] Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
  • [ISO-abbreviation] Clin Pediatr Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4004892
  • [Keywords] NOTNLM ; Infantile hypoglycemia / hyperinsulinism / nocturnal glucose infusion / octreotide
  •  go-up   go-down


99. He ZY, Li FY, Tong Q, Liao ZW, Guan XX, Wang Y: [Concurrent chemoradiotherapy with sodium glycididazole and cisplatin for local advanced nasopharyngeal carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Nov;28(11):2038-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • But at the end of the therapy, the chemoradiotherapy plus sodium glycididazole group showed a significantly higher rate of complete tumor remission than the chemoradiotherapy group (93.3% vs 73.33%, chi(2)=4.32, P=0.038).
  • CONCLUSION: Sodium glycididazole plus cisplatin can accelerate the tumor remission and improve the complete remission rate in patients with local advanced NPC without causing severe toxicity.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033122.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Radiation-Sensitizing Agents; 0 / sodium bimetrondazole glycinate; 140QMO216E / Metronidazole; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


100. Imai E, Yamagata K, Iseki K, Iso H, Horio M, Mkino H, Hishida A, Matsuo S: Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol; 2007 Nov;2(6):1360-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kidney disease screening and early intervention brought reduction of progressive glomerulonephritis or an increase in remission.
  • [MeSH-major] Kidney Diseases / diagnosis

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942780.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement